IMNN
Imunon IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.24M
P/E Ratio
—
EPS
$-4.52
Beta
2.03
52W High
$35.84
52W Low
$2.08
50-Day MA
$2.82
200-Day MA
$4.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
16.78
PEG Ratio
5.03
About Imunon Inc
Imunon Inc. is a clinical-stage biotechnology company specializing in the development of innovative immune-mediated therapies for cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune responses that promote effective tumor eradication. With a diverse pipeline of therapeutics undergoing various stages of clinical evaluation and established strategic collaborations, the company is poised to make significant contributions to the field of immunotherapy, potentially transforming patient outcomes and solidifying its competitive position within the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 125,000 |
| Gross Profit (TTM) | $2.72M |
| EBITDA | $-14.51M |
| Operating Margin | 0.00% |
| Return on Equity | -768.00% |
| Return on Assets | -124.40% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.67 |
| Price-to-Book | 2.75 |
| Price-to-Sales (TTM) | 17.94 |
| EV/Revenue | 4.004 |
| EV/EBITDA | 0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.20M |
| Float | $4.55M |
| % Insiders | 0.59% |
| % Institutions | 11.99% |
Historical Volatility
HV 10-Day
53.69%
HV 20-Day
47.09%
HV 30-Day
45.02%
HV 60-Day
47.98%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($17.60 target)
1
Strong Buy3
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026